ICHR
Ichor Holdings, Ltd.
ICHR's outlook is improving despite an expensive valuation.
MU
Micron Technology, Inc.
MU has the edge over ICHR overall, supported by stronger valuation and lower modeled downside.
ICHR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Weak | |
| Strong |
ICHR's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
MU Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
MU's revenue, profitability, cash flow and balance sheet are all currently strong.
ICHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $37.07 | — |
| Cheap | 13x | $0.63 | -98% |
| Fair | 20x | $1.01 | -97% |
| Expensive | 42x | $2.11 | -94% |
| Current | 741x | $37.07 | — |
Historical ranges are pointers, not guarantees.
ICHR's PE is in its expensive range at 741x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
MU PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 4.6x | $798 | — |
| Cheap | 10x | $777 | -2.7% |
| Current | 11x | $798 | — |
| Fair | 22x | $1,646 | +106% |
| Expensive | 32x | $2,404 | +201% |
Historical ranges are pointers, not guarantees.
MU has the edge over ICHR in the historical PE scenario, which offers more potential upside but is not a forecast.
ICHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for ICHR, with profitability improving.
MU Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Broad | |
| Moderate |
Analysts expect strong earnings and revenue growth for MU, with profitability improving.
ICHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.17 | +6237% |
| Q3 2026 | $0.05 | +$1.24 |
| Q2 2026 | -$1.17 | -$0.57 |
| Q1 2026 | -$1.48 | -$1.01 |
| Q4 2025 | -$1.54 | -$0.90 |
| Q3 2025 | -$1.19 | -$0.26 |
| Q2 2025 | -$0.60 | +$0.61 |
| Q1 2025 | -$0.47 | +$1.30 |
| Q4 2024 | -$0.64 | +$0.83 |
ICHR has returned to profit: it earned $0.05 per share over the past year, after losing money the year before.
MU Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $174.95 | +135% |
| Q3 2026 | $74.33 | +879% |
| Q2 2026 | $44.17 | +693% |
| Q1 2026 | $21.18 | +405% |
| Q4 2025 | $10.52 | +201% |
| Q3 2025 | $7.59 | +984% |
| Q2 2025 | $5.57 | +$6.99 |
| Q1 2025 | $4.19 | +$7.64 |
| Q4 2024 | $3.49 | +$9.77 |
MU has the edge over ICHR on earnings, with more consistent year-over-year improvement.
ICHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $328.7M | +37% |
| Q2 2026 | $294.8M | +23% |
| Q1 2026 | $256.1M | +4.7% |
| Q4 2025 | $223.6M | -4.2% |
| Q3 2025 | $239.3M | +13% |
| Q2 2025 | $240.3M | +18% |
| Q1 2025 | $244.5M | +21% |
| Q4 2024 | $233.3M | +15% |
ICHR's revenue is growing: $329M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.9% | +15 points |
| Q2 2026 | 2.4% | +4.4 points |
| Q1 2026 | 0.8% | +1.3 points |
| Q4 2025 | -6.2% | -5.7 points |
| Q3 2025 | -8.1% | -7.9 points |
| Q2 2025 | -2% | -0.9 points |
| Q1 2025 | -0.5% | +1.4 points |
| Q4 2024 | -0.5% | +3.4 points |
ICHR's operating margin was 6.9% last quarter, up 15 points from the same quarter a year ago.
MU Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $54.2B | +379% |
| Q2 2026 | $41.5B | +346% |
| Q1 2026 | $23.9B | +196% |
| Q4 2025 | $13.6B | +57% |
| Q3 2025 | $11.3B | +46% |
| Q2 2025 | $9.3B | +37% |
| Q1 2025 | $8.1B | +38% |
| Q4 2024 | $8.7B | +84% |
MU has the edge over ICHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 81% | +48 points |
| Q2 2026 | 80% | +57 points |
| Q1 2026 | 68% | +46 points |
| Q4 2025 | 45% | +20 points |
| Q3 2025 | 32% | +13 points |
| Q2 2025 | 23% | +13 points |
| Q1 2025 | 22% | +19 points |
| Q4 2024 | 25% | +49 points |
MU has the edge over ICHR on profitability, with a higher operating margin.
ICHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.5M | -1983% |
| Q2 2026 | -$23.6M | -$8.8M |
| Q1 2026 | -$10M | -2113% |
| Q4 2025 | $5.9M | +$12.8M |
| Q3 2025 | $2.1M | -3.3% |
| Q2 2025 | -$14.8M | -201% |
| Q1 2025 | $496K | +58% |
| Q4 2024 | -$6.9M | -119% |
ICHR's free cash flow was −$67M over the past year, against −$19M the year before.
MU Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $32.9B | +45543% |
| Q2 2026 | $17.6B | +951% |
| Q1 2026 | $5.5B | +$5.6B |
| Q4 2025 | $3B | +7853% |
| Q3 2025 | $72M | -75% |
| Q2 2025 | $1.7B | +322% |
| Q1 2025 | -$113M | +$52M |
| Q4 2024 | $38M | +$433M |
MU has the edge over ICHR on cash generation, producing positive trailing cash flow while its opponent burns cash.
ICHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.1% | +1.9M shares |
| 1 year | +11% | +3.8M shares |
| 3 years | +30% | +8.9M shares |
| 5 years | +31% | +9.1M shares |
| Available history | +67% | +15.4M shares |
ICHR has 38M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
MU Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -2M shares |
| 1 year | +1.6% | +18M shares |
| 3 years | +4.6% | +50M shares |
| 5 years | +0.2% | +2M shares |
| Available history | +1.2% | +14M shares |
MU has the edge over ICHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $350M |
| Q4 2025 | $300M |
| Q3 2024 | $300M |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
MU has spent almost nothing on buybacks in the past year.
ICHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.9x | Net Cash |
| Q2 2026 | -16.3x | Net Cash |
| Q3 2025 | 6.5x | High |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.9x | Very low |
| Q3 2024 | 0.8x | Very low |
| Q2 2024 | 1.1x | Healthy |
ICHR has the edge over MU on leverage, with a lower net debt burden relative to earnings.
MU Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.3x | Net Cash |
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | -0.1x | Net Cash |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2025 | 0.3x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
MU has more cash than debt.
ICHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 10.0 | Oversold |
ICHR's weekly RSI is 38 (neutral) and its Stochastic is 10 (oversold).
MU Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.1 | Neutral |
| Stochastic | 26.9 | Neutral |
MU's weekly RSI is 47 (neutral) and its Stochastic is 27 (neutral).
ICHR PE vs Technology Sector
| Metric | ICHR | Sector median | Relative |
|---|---|---|---|
| PE | 741x | 28x | 2,561% above |
| PE % | 100 | 35 | 65 pts above |
ICHR is trading at 741x earnings, a 2561% premium to the Technology sector's median of 28x.
MU PE vs Technology Sector
| Metric | MU | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 28x | 61% below |
| PE % | 18 | 35 | 17 pts below |
MU has the edge over ICHR on valuation relative to its sector.
ICHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.0 | 19% below |
| 20 week MA | $61.7 | 40% below |
| 50 week MA | $54.6 | 32% below |
| 100 week MA | $38.3 | 3.1% below |
| 200 week MA | $35.8 | 3.5% above |
ICHR has fallen below most of its moving averages, though it's still 3.5% above its 200-week average.
MU Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $914.5 | 13% below |
| 20 week MA | $931.0 | 14% below |
| 50 week MA | $685.9 | 16% above |
| 100 week MA | $405.4 | 97% above |
| 200 week MA | $246.0 | 225% above |
MU has the edge over ICHR on trend strength, trading above more of its moving averages.
ICHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.9 | $30.5 | -10% |
| 2021 | $30.5 | $45.5 | +49% |
| 2022 | $45.5 | $26.2 | -42% |
| 2023 | $26.2 | $33.6 | +28% |
| 2024 | $33.6 | $31.4 | -6.7% |
| 2025 | $31.4 | $19.0 | -40% |
| 2026 YTD | $19.0 | $37.1 | +96% |
ICHR is up 96% so far in 2026, after finishing lower in four of the previous six years.
MU Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.0 | $70.6 | +31% |
| 2021 | $70.6 | $94.4 | +34% |
| 2022 | $94.4 | $50.2 | -47% |
| 2023 | $50.2 | $85.3 | +70% |
| 2024 | $85.3 | $88.6 | +3.9% |
| 2025 | $88.6 | $284.8 | +221% |
| 2026 YTD | $284.8 | $798.4 | +180% |
MU has the edge over ICHR on returns for 2026, with the stronger performance.